Table 3 Toxicity by patient and by cycle NCI/CTC

From: Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

 

By patient

By cycle

Adverse events by NCI/CTC

Overall incidence N (%)

Grade 3 N (%)

Grade 4 N (%)

Overall incidence N (%)

Grade 3 N (%)

Grade 4 N (%)

Neutropenia

43 (87.8)

8 (16.3)

24 (49.0)

130 (50.4)

27 (10.5)

48 (18.6)

Leucopenia

44 (89.8)

15 (30.6)

12 (24.5)

159 (61.6)

44 (17.1)

15 (5.8)

Anaemia

48 (98.0)

5 (10.2)

1 (2.0)

224 (86.8)

7 (2.7)

1 (0.4)

Thrombocytopenia

26 (53.1)

1 (2.0)

2 (4.1)

58 (22.5)

5 (1.9)

2 (0.8)

Infection

 Neutropenic inf.

6 (12.2)

6 (12.2)

6 (2.3)

6 (2.3)

 Inf. without neutropenia

13 (26.5)

28 (10.8)

 Inf. other

1 (2.0)

1 (0.4)

 Catheter inf.

1 (2.0)

1 (2.0)

1 (0.4)

1 (0.4)

Gastrointestinal

 Nausea

42 (85.7)

1 (2.0)

124 (47.9)

1 (0.4)

 Vomiting

29 (59.2)

2 (4.1)

1 (2.0)

56 (21.6)

2 (0.8)

1 (0.4)

 Diarrhoea

26 (53.1)

1 (2.0)

53 (20.5)

1 (0.4)

 Dysphagia

11 (22.5)

7 (2.7)

 Anorexia

5 (10.2)

83 (32.1)

6 (2.3)

 Stomatitis

31 (63.3)

5 (10.2)

18 (7.0)

1 (0.4)

 Constipation

9 (18.4)

1 (2.0)

23 (8.9)

1 (0.4)

 Dyspepsia

9 (18.4)

1 (2.0)

11 (4.3)

 Mouth dryness

7 (14.3)

124 (47.9)

1 (0.4)

Dermatology

 Alopecia

45 (91.8)

NA

NA

NA

 Injection site reaction

19 (38.8)

1 (2.0)

39 (15.1)

1 (0.4)

Cardiovascular

 Phlebitis

1 (2.0)

1 (0.4)

1 (0.4)

 Arrhythmia

1 (2.0)

1 (2.0)

1 (0.4)

1 (0.4)

Neurological

 Dizziness

6 (12.2)

9 (3.5)

 Neurosensory

9 (18.4)

21 (8.1)

 Vertigo

5 (10.2)

9 (3.5)

Constitutional

 Fatigue

38 (77.6)

3 (6.1)

140 (54.1)

6 (2.3)

 Fever in the absence of neutropenia

7 (14.3)

7 (2.7)

Pain

 Abdominal

10 (20.4)

16 (6.2)

 Arthralgia

6 (12.2)

2 (4.1)

16 (6.2)

2 (0.8)

 Headache

9 (18.4)

1 (2.0)

21 (8.1)

1 (0.4)

 Myalgia

8 (16.3)

19 (7.3)

 Pain other

6 (12.2)

13 (5.0)

  1. NA=not applicable.
  2. NCI/CTC =National Cancer Institute/Common Toxicity Criteria. In all, 258 cycles were evaluable for haematological toxicity.
  3. In all, 259 cycles were evaluable for nonhaematological toxicity.